Citi lowered the firm’s price target on Mersana Therapeutics to $5 from $6 and keeps a Buy rating on the shares. The analyst updated models in Smid-cap biotechnology following the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics price target lowered to $3 from $4 at Baird
- Mersana Therapeutics Releases Updated Corporate Presentation
- Mersana Therapeutics sees cash runway into 2026
- Mersana Therapeutics reports Q2 EPS (20c), consensus (17c)
- Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results